secwatch.observer — SEC 8-K summary ====================================== Issuer: MiniMed Group, Inc. (MMED) CIK: 0002062583 Form: 8-K Filed at: 2026-11-16T14:18:26+00:00 Accession: 0001104659-26-127725 Event type: regulatory Sentiment: neutral Materiality: 0.70 Item codes: 7.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 MiniMed FDA-cleared for MiniMed Fit tubeless pump; $162M charge cuts FY2027 adj EBITDA margin guide to ~11.3% -------------------------------------------------------------------------------- - FDA cleared MiniMed Fit, the company's first tubeless insulin pump: up to seven days of wear, 300-unit insulin capacity, app control and SmartGuard technology. - Clearance came several months ahead of expectations; U.S. launch now planned for Spring 2027, ahead of the previously communicated Summer 2027 timing. - A one-time $162M charge hits fiscal Q3 2027, tied to the minimum payment owed under the R&D agreement with Blackstone Life Sciences affiliates assumed in the Medtronic separation. - FY2027 adjusted EBITDA margin guidance cut to approximately 11.3% from approximately 16%; MiniMed says the change solely reflects the $162M charge, not operating performance. - The charge is an income-statement recognition of the obligation; associated cash payments will be made over time based on product sales and other agreement terms. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/2062583/000110465926127725/0001104659-26-127725-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/2062583/000110465926127725/tm2629842d1_8k.htm HTML page: https://secwatch.observer/filing/0001104659-26-127725 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer